*Adverse events occurred for the ﬁrst time or worsened after the ﬁrst dose of exenatide once-weekly during the open-label period. /C160n(%) events for frequent adverse events. /C224n(%) for individual treatment-emergent adverse events leading to withdrawal (withdrawal may have occurred after week 52).DIABETIC Medicine Original article ª2011 Amylin Pharmaceuticals, Inc. Diabetic Medicine ª2011 Diabetes UK 711